After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...